ARTICLE | Deals
At least seven molecular glue degrader deals announced this year; less deal activity for classical PROTACs
By Karen Tkach Tuzman, Director of Biopharma Intelligence
October 31, 2024 7:55 PM UTC
Deal activity for targeted protein degraders this year has tilted toward “molecular glues” over chimeric degrader formats such as PROTACs, and the terms and indications for the seven glue transactions announced in 2024 — three of them in the last month — reflect the maturation of the field.
The two main types of targeted protein degraders, glues and chimeras, have each been a growing focus for industry over the last decade, including large pharmas getting in via deals. “Now they’re part of everyone’s toolbox,” C4 Therapeutics Inc. (NASDAQ:CCCC) CEO Andrew Hirsch told BioCentury…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653987/trend-watch-degrader-deals-show-glues-are-sticking